This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, T. Articles by Dang, N. H. Search for Related Content PubMed PubMed Citation Articles by Sato, T. Articles by Dang, N. H.

CD26 Regulates p38 Mitogen-Activated Protein Kinase–Dependent Phosphorylation of Integrin ß₁, Adhesion to Extracellular Matrix, and Tumorigenicity of T-Anaplastic Large Cell Lymphoma Karpas 299

¹ Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, Texas and ² Department of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Requests for reprints: Nam H. Dang, Department of Hematologic Oncology, Nevada Cancer Institute, 10000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135. Phone: 702-821-0000; Fax: 702-821-0021; E-mail: ndang{at}nvcancer.org.

CD26 is an antigen with key role in T-cell biology and is expressed on selected subsets of aggressive T-cell malignancies. To elucidate the role of CD26 in tumor behavior, we examine the effect of CD26 depletion by small interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299. We show that the resultant CD26-depleted clones lose the ability to adhere to fibronectin and collagen I. Because anti–integrin ß₁ blocking antibodies also prevent binding of Karpas 299 to fibronectin and collagen I, we then evaluate the CD26-integrin ß₁ association. CD26 depletion does not decrease integrin ß₁ expression but leads to dephosphorylation of both integrin ß₁ and p38 mitogen-activated protein kinase (MAPK). Moreover, our data showing that the p38MAPK inhibitor SB203580 dephosphorylates integrin ß₁ and that binding of the anti-CD26 antibody 202.36 dephosphorylates both p38MAPK and integrin ß₁ on Karpas 299, leading to loss of cell adhesion to the extracellular matrix, indicate that CD26 mediates cell adhesion through p38MAPK-dependent phosphorylation of integrin ß₁. Finally, in vivo experiments show that depletion of CD26 is associated with loss of tumorigenicity and greater survival. Our findings hence suggest that CD26 plays an important role in tumor development and may be a novel therapeutic target for selected neoplasms.

This article has been cited by other articles:

				J. Zhou, Y. Chen, J.-Y. Lang, J.-J. Lu, and J. Ding Salvicine Inactivates {beta}1 Integrin and Inhibits Adhesion of MDA-MB-435 Cells to Fibronectin via Reactive Oxygen Species Signaling Mol. Cancer Res., February 1, 2008; 6(2): 194 - 204. [Abstract] [Full Text] [PDF]